Grab Holdings Ltd. vs Tempus AI — how do they compare? Grab Holdings Ltd. trades at $3.13 (market cap $12.72B), while Tempus AI trades at $70.24 (market cap $12.58B). The key difference: Grab Holdings Ltd. and Tempus AI are close in size by market cap, and Tempus AI is trading nearer its 52-week high, Grab Holdings Ltd. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Grab Holdings Ltd. for 94 Days and Tempus AI for 22 Days on average.
| GRAB | TEM | |
|---|---|---|
Market Cap | $12.72B | $12.58B |
Volume | 65,352,859 | 7,444,569 |
Sector | Technology | Broad Market / Factor |
52-Week High | $6.17 | $99.28 |
52-Week Low | $2.80 | $41.55 |
Typical Hold Time | 94 Days | 22 Days |
Enterprise Value | $8.46B | $13.21B |
Signals from Pluang's Aura AI — not financial advice
GRAB trades at $3.08, up 0.33% with bearish technical signals but strong fundamentals. The company achieved profitability in 2025 with $268M net income and has beaten earnings estimates for three consecutive quarters. Recent developments include a $1.49B acquisition of Atome Financial and $30M in insider buying by the CEO, signaling confidence in growth prospects despite recent stock pressure.
GRAB presents a compelling turnaround story with accelerating revenue growth and margin expansion. The risk-reward appears favorable given the 92% analyst buy rating, though investors should monitor integration risks from the Atome acquisition and competitive pressures in Southeast Asian markets that could impact future profitability.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite recent weakness. The company reported Q2 2026 revenue growth of 22% year-over-year and beat EPS estimates for three consecutive quarters, though it remains unprofitable with a net income margin of -17.77%. Recent positive developments include FDA clearance for its ECG-MR AI product and expanded data licensing agreements, fueling investor optimism in the healthtech sector.
The investment outlook is cautiously optimistic, driven by strong analyst support (64% buy ratings) and a consensus price target of $72.60, implying modest upside. Key opportunities include accelerating adoption of AI-powered diagnostics and strategic acquisitions, but risks persist from persistent cash burn, insider selling, and intense competition in the precision medicine space.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →